Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of luseogliflozin on glucagon secretion after meals in type 2 diabetes
jRCTs031190010Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of luseogliflozin in type 2 diabetes mellitus (T2DM), sponsored by Taisho Pharmaceutical. Primary endpoint: Change in glucagon secretion pattern after meal. Started May 2016; status: completed.
02
Drugs
luseogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs031190010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190010.